TY - JOUR
T1 - Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens
AU - Ito, Keiichi
AU - Yoshii, Hidehiko
AU - Asakuma, Junichi
AU - Sato, Akinori
AU - Horiguchi, Akio
AU - Sumitomo, Makoto
AU - Hayakawa, Masamichi
AU - Asano, Tomohiko
PY - 2009
Y1 - 2009
N2 - Objective: Renal cell carcinoma (RCC) with a high-nucleolar-grade component is considered to be an aggressive type of tumor. In the present study, we evaluated the impact of the presence of the worst-nucleolar-grade component and also tried to determine predictors for recurrence and prognosis in patients with the worst grade component. Methods: We evaluated 314 patients with RCC. A three-graded system was used for nucleolar grading, the patients were classified into four groups according to the presence of the worst nucleolar grade (Grade 3) and the occupancy of each grade, and clinicopathological factors and clinical outcomes were compared. In patients of Grade 3 components (Groups 1 and 2), factors influencing on prognosis and recurrence were evaluated by multivariate analysis. Results: There was no significant difference in clinicopathological factors between Group 1 (with Grade 3-dominant tumors) and Group 2 (with tumors in which Grade 1 or 2 was dominant and there were Grade 3 components). Neither did cause-specific survival or recurrence-free survival differ significantly between those two groups. In multivariate analysis, only distant metastasis was an independent predictor for prognosis in all patients with Grade 3 components. Moreover, an elevated C-reactive protein (CRP) level (≥1 mg/dl) was the only independent predictor of recurrence in NOMO patients. Conclusions: Regardless of dominancy, the presence of the worst grade component has a significant clinical impact in RCC patients. NOMO patients whose RCC has worst-grade components but whose CRP levels are <1 are expected to have longer recurrence-free intervals and to survive longer than those whose CRP levels are higher.
AB - Objective: Renal cell carcinoma (RCC) with a high-nucleolar-grade component is considered to be an aggressive type of tumor. In the present study, we evaluated the impact of the presence of the worst-nucleolar-grade component and also tried to determine predictors for recurrence and prognosis in patients with the worst grade component. Methods: We evaluated 314 patients with RCC. A three-graded system was used for nucleolar grading, the patients were classified into four groups according to the presence of the worst nucleolar grade (Grade 3) and the occupancy of each grade, and clinicopathological factors and clinical outcomes were compared. In patients of Grade 3 components (Groups 1 and 2), factors influencing on prognosis and recurrence were evaluated by multivariate analysis. Results: There was no significant difference in clinicopathological factors between Group 1 (with Grade 3-dominant tumors) and Group 2 (with tumors in which Grade 1 or 2 was dominant and there were Grade 3 components). Neither did cause-specific survival or recurrence-free survival differ significantly between those two groups. In multivariate analysis, only distant metastasis was an independent predictor for prognosis in all patients with Grade 3 components. Moreover, an elevated C-reactive protein (CRP) level (≥1 mg/dl) was the only independent predictor of recurrence in NOMO patients. Conclusions: Regardless of dominancy, the presence of the worst grade component has a significant clinical impact in RCC patients. NOMO patients whose RCC has worst-grade components but whose CRP levels are <1 are expected to have longer recurrence-free intervals and to survive longer than those whose CRP levels are higher.
UR - http://www.scopus.com/inward/record.url?scp=69949116350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69949116350&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyp068
DO - 10.1093/jjco/hyp068
M3 - Article
C2 - 19556339
AN - SCOPUS:69949116350
SN - 0368-2811
VL - 39
SP - 588
EP - 594
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 9
ER -